NCT06426797View on ClinicalTrials.gov

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2027

Conditions
Locally Advanced Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Cadonilimab plus anlotinib

cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles

Sponsors
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Peking University People's Hospital

OTHER